Diagnosed and Drug-Treated Prevalence of Essential Tremor in Pediatric Patients: Retrospective Analyses of Two US Healthcare Claims Databases
Objective: Estimate the prevalence of diagnosed and drug-treated essential tremor (ET) in the pediatric population using 2 US healthcare claims databases. Background: An ET diagnosis…Preclinical Characterization of Suvecaltamide for Essential Tremor
Objective: To characterize the in vitro T-type calcium (CaV3) channel target pharmacology and in vivo anti-tremor profile of suvecaltamide (JZP385, CX-8998). Background: CaV3 channels, a…Initial experience with levodopa-entacapone-carbidopa intestinal gel infusion (LECIG) for the management of advanced Parkinson’s disease in Slovenia
Objective: To study the initial experience with levodopa-entacapone-carbidopa intestinal gel infusion (LECIG) in routine clinical practice at two University Medical Centers in Slovenia. Background: The…Statin use and incidence of Parkinson’s disease in women from the French E3N cohort study
Objective: To examine whether incident statin use is associated with lower Parkinson’s disease (PD) incidence while considering the potential for reverse causation. Background: Drug repurposing…Phase 2 study evaluating safety, PK/PD, biomarkers, and efficacy of ANX005 in patients with Huntington’s disease (HD)
Objective: To assess the safety, PK/PD, exploratory biomarkers, and efficacy of ANX005 in patients with, or at risk for, manifest HD. Background: Increased complement activation…Association between dihydropyridines and dementia conversion in Parkinson’s disease
Objective: To investigate the role of antihypertensive drugs, including dihydropyridines, on nigrostriatal dopamine and dementia conversion in Parkinson's disease Background: Several experimental and clinical studies…Levodopa-carbidopa intestinal gel infusion and long-term tolerability in Parkinson’s: multicentre, international 13-year follow-up data
Objective: To evaluate the long-term range and nature of Levodopa-carbidopa intestinal gel (LCIG) infusion-related complications in people with Parkinson’s (PwP). Background: LCIG infusion is an…Continuous circadian intracerebroventricular administration of anaerobically preserved dopamine greatly reduces severe L-dopa-related complications in Parkinson’s disease
Objective: We aim to demonstrate the safety and efficacy of continuous circadian intracerebroventricular (i.c.v.) administration of anaerobic-dopamine (A-dopamine) to reduce the L-dopa-related complications (LDRC) in…Efficacy of levodopa/benserazide dispersible tablet on delayed ON in Parkinson’s disease patients with motor fluctuations: a multicenter randomized open-label cross-over trial
Objective: This study aimed to assess the efficacy of levodopa/benserazide dispersible tablet on delayed ON in Parkinson’s disease (PD) patients with motor fluctuation. Background: Delayed…Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson’s disease: TALISMAN study rationale and protocol
Objective: This is the first study that will assess the potential impact of hypoxia-based therapy in individuals with PD on respiratory parameters and PD symptoms.…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 32
- Next Page »